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ABSTRACT
Objectives: The objective of this trial was to investigate the safety and preliminary
effectiveness of a daily dose of 300 mg of tenofovir disoproxil fumarate (TDF) versus placebo in
preventing HIV infection in women.
Design: This was a phase 2, randomized, double-blind, placebo-controlled trial.
Setting: The study was conducted between June 2004 and March 2006 in Tema, Ghana;
Douala, Cameroon; and Ibadan, Nigeria.
Participants: We enrolled 936 HIV-negative women at high risk of HIV infection into this
study.
Intervention: Participants were randomized 1:1 to once daily use of 300 mg of TDF or
placebo.
Outcome measures: The primary safety endpoints were grade 2 or higher serum creatinine
elevations (.2.0 mg/dl) for renal function, grade 3 or 4 aspartate aminotransferase or alanine
aminotransferase elevations (.170 U/l) for hepatic function, and grade 3 or 4 phosphorus
abnormalities (,1.5 mg/dl). The effectiveness endpoint was infection with HIV-1 or HIV-2.
Results: Study participants contributed 428 person-years of laboratory testing to the primary
safety analysis. No significant differences emerged between treatment groups in clinical or
laboratory safety outcomes. Study participants contributed 476 person-years of HIV testing to
the primary effectiveness analysis, during which time eight seroconversions occurred. Two
were diagnosed in participants randomized to TDF (0.86 per 100 person-years) and six in
participants receiving placebo (2.48 per 100 person-years), yielding a rate ratio of 0.35 (95%
confidence interval ¼ 0.03–1.93), which did not achieve statistical significance. Owing to
premature closures of the Cameroon and Nigeria study sites, the planned person-years of
follow-up and study power could not be achieved.
Conclusion: Daily oral use of TDF in HIV-uninfected women was not associated with increased
clinical or laboratory adverse events. Effectiveness could not be conclusively evaluated because
of the small number of HIV infections observed during the study.
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
www.plosclinicaltrials.org May | 2007 | e270001
PLoS CLINICAL TRIALS
INTRODUCTION
The HIV epidemic is continuing to grow worldwide [1].
Consistent and correct use of condoms is recommended for
prevention of sexually transmitted HIV, but often women are
unable to negotiate condom use with their male partners.
Safe, effective, and easy to use methods of HIV prevention are
urgently needed, especially for women.
Tenofovir disoproxil fumarate (TDF) [2], the orally
bioavailable prodrug of tenofovir, is metabolized to a
competitive inhibitor of viral reverse transcriptase. TDF was
selected for clinical development as a treatment for HIV
infection because of its (1) potency against wild-type HIV and
some nucleoside-resistant strains of HIV [3–6], (2) low
potential of selecting for TDF-resistant mutants [7], (3) low
likelihood of metabolic/mitochondrial toxicity [8], and (4)
pharmacologic profile supporting daily dosing [2]. TDF was
licensed for the treatment of established HIV-l infection by
the United States Federal Drug Administration in 2001, and
the European Commission issued a marketing authorization
in 2002 [9]. TDF has since been used worldwide for treatment
of HIV infection, accounting for nearly 500,000 patient-years
of observation [10].
We investigated the safety and effectiveness of a daily dose
of 300 mg of TDF in preventing HIV infection among women
at high risk for infection based on the following rationale: (1)
initial prevention studies in simian models have provided
support for both pre- and post-exposure efficacy of TDF in
preventing retroviral infections [11–14]; (2) TDF has been
shown to be safe in large numbers of HIV-infected persons
[15,16]; (3) TDF is dosed conveniently once a day; (4) TDF has
no known interactions with hormonal contraception [17]; (5)
a high barrier to resistance was seen in clinical trials of HIV
treatment, with the primary mutation identified (K65R)
resulting in a reduction of viral replication to almost half
that of wild-type [18]; and (6) the drug’s sponsor, Gilead
Sciences, is supportive of investigating the potential use of
TDF as a preventive agent. Moreover, should it prove to be
effective for HIV prevention, Gilead Sciences has committed
to making TDF available in resource-poor settings for public
health use, as they currently do for treatment of HIV, via no-
profit pricing and licensing agreements.
METHODS
Participants
Study participants were recruited from areas within each city
that were considered high HIV transmission areas, including
markets, bars, and hotels. Although we did not specifically ask
as part of the clinical trial procedures if the participants were
sex workers, most exchanged sex for money. Special ethical
considerations were taken into account because of the
potential vulnerability of this population. We developed
strategies to protect the confidentiality and autonomy of the
participants, increase/ensure comprehension of the informed
consent and research methods, and promote access to
resources and services during and after the trial.
We enrolled HIV-antibody-negative women 18 to 35 y old
who were at risk of HIV infection by virtue of having an
average of three or more coital acts per week and four or
more sexual partners per month. Participants had to be
willing to use the study drug as directed and participate for
www.plosclinicaltrials.org May | 2007 | e270002
TDF for Prevention of HIV in Women
Editorial Commentary
Background: The World Health Organization has estimated that in
2006 around 4.3 million people were newly infected with HIV. Infection
rates seem to be increasing in some countries, and there is an urgent
need to find safe and effective ways of preventing HIV from being
transmitted from one person to another. Many strategies for the
prevention of HIV transmission between adults, such as use of
condoms or changes to behavior, are not completely reliable, and
women, in particular, may not always be able to negotiate condom
use. Additional strategies for reducing the risk of HIV transmission are
needed. One of these strategies is called ‘‘pre-exposure prophylaxis.’’
This strategy involves individuals who are at high risk of becoming
infected with HIV taking antiviral drugs to prevent HIV infection. One
particular drug, tenofovir disoproxil fumarate, is currently approved as
a treatment for HIV infection, and is also being investigated as a strong
candidate for pre-exposure prophylaxis. The research presented here
reports on results of a trial carried out at three different sites in Ghana,
Cameroon, and Nigeria. In the trial, 936 women who were not infected
with HIV but who were at high risk of becoming infected, were
randomized to take tenofovir tablets daily or, alternatively, placebo
tablets. The researchers planned to follow up with the women for 12
months, and the primary analysis for efficacy would focus on a
comparison of the rate of new HIV infections between the two arms of
the trial. Primary safety analyses included specific laboratory tests
carried out on blood samples that might point to abnormalities in liver
or kidney function. Safety data were also collected throughout the trial,
and health problems that arose were classified as adverse events or
serious adverse events.
What this trial shows: Unfortunately, this trial was not completed as
planned. Two sites (Nigeria and Cameroon) were closed either before the
planned number of participants had been recruited or before all
participants had completed full follow-up. Therefore, not enough data
were available from this trial to determine whether tenofovir reduced the
risk of HIV infection. Only two sites contributed data for the primary
safety analyses, which looked at liver and kidney function. The
researchers did not see any statistically significant differences in these
safety endpoints between participants taking tenofovir and those taking
placebo. There were also no statistically significant differences between
the treatment groups in the number of adverse events. The main efficacy
analysis found two new HIV infections in the tenofovir group and six in
the placebo group. Because only eight effectiveness endpoints were
observed during this study, the difference in HIV incidence between
these groups was not statistically significant.
Strengths and limitations: A strength of this trial is that it was correctly
designed to address the original objectives of the study, involving
appropriate concealment of randomization and blinding of participants
and study staff to treatment assignment. The main limitation of this
study was the closure of two study sites, which meant that the study did
not have sufficient power to assess differences between trial arms in the
primary efficacy analysis.
Contribution to the evidence: At the time this trial was completed,
there was no other evidence from randomized studies that evaluated
antiretroviral drugs for prevention of HIV infection. This trial cannot,
however, definitively address whether tenofovir reduces the risk of HIV
infection among at-risk women or not. Ongoing and future trials are
essential in order to answer this question. The trial reported here
provides important data on the safety of daily tenofovir among high-risk
HIV-uninfected women; the safety data are encouraging and suggest
that tenofovir use is not associated with increased adverse events as
compared to placebo.
The Editorial Commentary is written by PLoS staff, based on the reports of the
academic editors and peer reviewers.
up to 12 mo of follow-up. Because TDF has been associated
with rare episodes of renal disorders, increased liver enzymes,
and hypophosphatemia, participants were also required to
have adequate renal function (serum creatinine , 1.5 mg/dl),
liver function (aspartate aminotransferase [AST] and alanine
aminotransferase [ALT] , 43 U/l), and serum phosphorus
(2.2 mg/dl) at their screening visit. Since no adequate and
well-controlled studies of TDF have been conducted in
pregnant women, participants were not enrolled if pregnant
or breastfeeding, or wishing to become pregnant during the
12 mo of study participation.
During recruitment, study staff explained the general
purpose of the study and the eligibility requirements. If
eligible, women were referred to the study clinic at each of
the three study sites. At the screening visit, women completed
written informed consent, received HIV pretest and condom
counseling, and underwent oral mucosal transudate (OMT)
rapid HIV testing. All participants received HIV post-test
counseling, a physical and pelvic examination, urine preg-
nancy tests, and assessment of hepatic and renal function.
Women with reactive OMT rapid HIV tests received ELISA to
confirm HIV status. Potential participants were asked to
return 4 wk after their screening visit to receive the results of
their hepatic and renal function tests and, if applicable, a
confirmatory HIV test. At this second visit, participants
signed or marked a consent form for enrollment, received
HIV counseling, provided urine for pregnancy testing, and
provided another OMT sample for HIV testing.
All participants provided written informed consent in their
preferred language. Illiterate participants were read the
informed consent forms verbatim in the presence of a
witness, and provided a mark or thumbprint in lieu of
signature. The study protocol and informed consent forms
were approved by the Ghana Health Service Ethical Review
Committee, Accra, Ghana; the National Ethics Review
Committee, Ministry of Public Health, Yaounde´, Cameroon;
the University of Ibadan/University College Hospital Institu-
tional Review Board, Ibadan, Nigeria; and the Protection of
Human Subjects Committee, Family Health International
(FHI), Durham, North Carolina, United States.
At each monthly follow-up visit, participants underwent
OMT HIV and pregnancy testing, adverse event (AE) assess-
ment, risk reduction counseling, and study drug and condom
re-supply. Clinic staff counseled participants to take one pill
every day, distributed condoms, and emphasized that
condoms should be used for all sexual contacts with all
partners because they were using a product of unknown or no
effectiveness for preventing HIV. Participants responded to
structured questionnaires on their sexual behavior and their
experience taking the pills during the previous 30 d, and were
reminded of study concepts discussed during the informed
consent process. At months 1, 3, 6, 9, 12, and as needed,
participants underwent physical examination and blood was
drawn for laboratory assessment of hepatic and renal
function. We discontinued product use for any participant
who had a reactive rapid HIV or positive pregnancy test
result. Pregnant women were allowed to resume study drug
use after their pregnancy had ended, providing they were not
breastfeeding. Study staff at each study site referred and
offered to escort participants who became infected with HIV
during the study to HIV-related psychological, social, and
medical services, such as viral load, CD4 level, and HIV
resistance testing in their communities, as well as antiretro-
viral drug provision when needed. Immediately after a
participant missed a scheduled follow-up appointment, study
staff made up to three attempts to contact that participant
and reschedule the clinic appointment (ideally to occur
within 1 wk of the original appointment).
Objective and Interventions
The objective of this trial was to investigate the safety and
preliminary effectiveness of a daily dose of 300 mg of TDF
versus placebo in HIV-uninfected women.
Outcomes
Protocol-defined primary safety endpoints included grade 2
or higher serum creatinine elevations (.2.0 mg/dl) for renal
function, grade 3 or 4 AST or ALT elevations (.170 U/l) for
hepatic function, and grade 3 or 4 phosphorus abnormalities
(,1.5 mg/dl).
After the study began, the TDF prescribing information
was amended to reflect a concern that people with chronic
hepatitis B virus (HBV) infection are at risk of developing
reactivation (i.e., flares) of hepatic disease after stopping use
of TDF. To monitor for potential flares, we amended our
protocol to add HBV surface antigen (HBsAg) testing for all
enrolled participants at the time of product discontinuation,
and ALT/AST monitoring for 3 mo after product discontin-
uation among HBsAg-positive participants. This amendment
was implemented only at the Ghana site in August 2005,
which was the only active study site (i.e., on drug) at the time.
The effectiveness endpoint was infection with HIV-1 or
HIV-2, measured by detecting antibodies in OMT (OraQuick
ADVANCE Rapid HIV-1/2 Antibody Test, Orasure Technol-
ogies, http://www.orasure.com) and confirmed by an enzyme-
linked immunosorbent assay (ELISA) (Genetic Systems HIV-1/
HIV-2 Plus O ELISA, Bio-Rad, http://www.bio-rad.com) or
Western blot (Genetic Systems HIV-1 Western Blot, BioRad)
from a finger prick or blood serum specimen. Discordant
results between the rapid antibody and the ELISA assays were
resolved with Western blot testing.
Sample Size
We designed the study to have 90% power to conclude with
95% confidence that TDF reduced the rate of HIV infection
by 50% (i.e., power to obtain a one-sided 95% upper
confidence limit for the rate ratio that is less than 0.5) if
the true rate of reduction due to TDF was at least 83%. The
planned sample size was 1,200 participants (400 per site), with
12 mo of follow-up for each participant. Based on prior work
with high-risk women in Cameroon [19], we assumed that the
HIV incidence rate in the placebo group would be no less
than five per 100 person-years, and that follow-up would be at
least 80% at 12 mo. Under these assumptions, we expected
that we would reach the required number of incident HIV
infections (30) to achieve 90% power. Owing to premature
closures of the Cameroon and Nigeria study sites, however,
the planned person-years of follow-up and study power could
not be achieved. Consequently, the primary effectiveness
analysis was revised to a traditional two-sided test of non-zero
effectiveness at the 0.05 significance level. The decision to
change the primary effectiveness analysis was made by the
project leader and statistician before unblinding the study.
For non-HIV safety outcomes, the planned sample size
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would have provided approximately 90% power to detect a
doubling in the proportion of women experiencing any
particular adverse reaction, if the proportion experiencing
the reaction in the placebo arm was 0.05 or more. However,
due to early termination of the study in Cameroon and
Nigeria, we had only approximately 70% power to detect
such a difference.
Randomization and Blinding
A randomization manager not otherwise involved in the study
developed a random allocation sequence using a permuted-
block design stratified by site, with random block sizes of 12,
18, and 32. A copy of the randomization list was sent to the
manufacturer, who filled each drug bottle with a 30-d supply
of TDF or placebo (12 bottles per randomization number).
Placebo tablets were identical to the TDF tablets in size,
shape, color, and taste. Each drug bottle was marked with a
sequential randomization number, but no product identifier.
Participants, field study staff, monitors, statisticians, and
other FHI staff involved in the trial were blinded to drug
assignment. Study staff assigned each eligible participant the
next sequential number, and gave her the first month’s supply
of study drug after she had fully qualified for the study and
signed or marked the enrollment consent form.
Statistical Methods
Primary safety analyses were based on time to grade 2 or
higher abnormalities for creatinine or grade 3 or higher
abnormalities for ALT, AST, and phosphorus, by site, using
exact two-sided log-rank tests computed in StatXact Version
7 (Cytel, http://www.cytel.com). Because of irregularities in the
performance of the laboratory in Nigeria, data from that site
were excluded from the primary safety analyses. The project
leader and study statistician made this decision before
unblinding the study.
The primary effectiveness analysis was based on an exact
log-rank test of no difference in the distribution of HIV-free
survival times, with data pooled across all three sites. Each
laboratory abnormality and HIV infection date was estimated
as the midpoint between the date of the first positive test
result and the previous, negative test date. A right censoring
time of 12 mo was applied in Ghana, corresponding to the
treatment regimen. For all participants in Cameroon and
Nigeria, the censoring date was the date of permanent
product withdrawal (4 February 2005 and 7 March 2005,
respectively). Secondarily, exact confidence intervals for the
relative risk of HIV, laboratory abnormalities, and AEs within
system organ classes were computed under a Poisson
assumption for the event rates in each treatment group. All
primary and secondary analyses were based on two-sided tests
and conducted at the 0.05 significance level.
Protocol-specified interim safety analyses occurred in April
and December 2005. An independent Data Monitoring
Committee, with access to treatment assignments, reviewed
AEs and primary safety and effectiveness outcomes. The
committee did not recommend changes in study procedures
after either analysis.
FHI monitors (trained in Good Clinical Practice) visited the
sites regularly to review study eligibility, informed consent,
protocol compliance, laboratory procedures, source docu-
ments, and AEs. We attempted to get original hospital
records, when available, for serious adverse events (SAEs)
and deaths.
RESULTS
Participant Flow, Numbers Analyzed, and Baseline
Characteristics
A total of 2,040 women were screened for inclusion in the
study (Figure 1). The Ghana site completed planned enroll-
ment (n ¼ 400) in December 2004. Routine follow-up
procedures continued monthly for 1 y, after which 3 mo of
off-product monitoring of liver function was continued for
the 56 HBsAg-positive participants. The Cameroon site
completed enrollment (n ¼ 400) in December 2004, before
the Ministry of Health suspended study drug distribution in
February 2005. In Nigeria, 136 of the planned 400 partic-
ipants were enrolled before site closure. Loss to follow-up was
17.3% (19.2% in the TDF group and 15.4% in the placebo
group, p¼0.11). Among these were 77 participants who never
returned after their enrollment visit and were therefore
excluded from the primary safety and effectiveness analyses.
No participants were discontinued from the study by the site
investigator or study clinician because of an AE or abnormal
laboratory result. Participants enrolled into the TDF and
placebo groups were similar in important demographic
respects (Table 1).
Recruitment
We enrolled participants into this study between June 2004
and March 2005. The last participant visit occurred in Ghana
in March 2006. In Cameroon, the Ministry of Health
suspended study drug distribution in February 2005 primarily
in response to concerns about the standard of long-term
post-trial care that could be guaranteed to seroconverters.
Participants continued to come to the clinic for off-product
laboratory, pregnancy, and HIV testing, and HIV prevention
counseling and condom distribution until September 2005, at
which time the Cameroon site was closed. In Nigeria, because
of repeated noncompliance with the protocol that was not
resolved with staff retraining, enrollment was stopped in
March 2005, and the site was closed thereafter.
Sexual Behavior
During screening, participants reported an average of 12
coital acts per week with an average of 21 sexual partners in
the previous 30 d (including 11 new partners). During follow-
up, participants reported an average of 15 coital acts per
week, with an average of 14 sexual partners in the previous 30
d (six new partners). Self-reported condom use increased
from 52% at screening (average across all sites during the last
coital act prior to screening) to approximately 92% at the
enrollment, month 3, month 6, and month 9 visits, to 95% at
the month 12 visit (for acts occurring during the last 7 d). The
average condom use during the follow-up period was 92%.
The overall pregnancy rate during follow-up was 52 per 100
person-years.
Product Use
The amount of product used was estimated by subtracting the
number of pills returned from the number dispensed, and
dividing this number by the total number of days in the
effectiveness analysis. Based on this calculation, drug was
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used for no more than 69% of all study days (78% in
Cameroon, 68% in Ghana, and 50% in Nigeria). Excluding
time off product due to pregnancy, drug was used for no
more than 74% of study days. Missed/late clinic visits and
pregnancy were the principal documented reasons for time
off product.
Safety
Hepatic and renal function. Analysis of hepatic and renal
function was restricted to data from Ghana and Cameroon,
which resulted in 210.2 person-years of follow-up in the TDF
group and 217.6 person-years in the placebo group. We did
not find significant differences in the primary safety
endpoints between treatment groups (Table 2). Specifically,
none of the 363 participants assigned to TDF in Ghana or
Cameroon had grade 3 or higher (.170 U/l) ALT or AST
elevations before product withdrawal, whereas two and three
of the 368 participants in the placebo group had grade 3þ
ALT and AST elevations, respectively. The percentage of
grade 1 or higher (.42 U/l) ALT and AST abnormalities was
greater in the TDF group, but the difference did not achieve
statistical significance. One participant in the TDF group had
a grade 3þ decrease in phosphorus (,1.5 mg/dl), which
spontaneously resolved to normal within 3 mo (study product
was not withdrawn). No participants in either group had a
grade 2þ creatinine elevation (.2.0 mg/dl). We did not find
significant differences in laboratory abnormalities between
treatment groups when the data were stratified by site,
although significantly more grade 1 AST and phosphorus
abnormalities occurred in Ghana than in Cameroon, and
significantly more grade 1 creatinine abnormalities occurred
in Cameroon than in Ghana.
Among the 56 participants who tested positive for HBsAg,
23 were in the TDF group and 33 in the placebo group. The
mean and median ALT and AST levels were not significantly
different between groups immediately before or after
discontinuation of study drug. Four ALT/AST abnormalities
(none over grade 1 [.42 U/l]) occurred within 3 mo after
discontinuation of study drug in HBsAg-positive participants;
one was in the TDF group and three were in the placebo
group.
In Cameroon, study drug was stopped before the imple-
mentation of the protocol amendment that included HBsAg
testing. We therefore monitored liver function for several
Figure 1. Participant Trial Flow Diagram
doi:10.1371/journal.pctr.0020027.g001
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months after product withdrawal in all participants, regard-
less of HBV status. The mean and median ALT and AST levels
were not significantly different between groups immediately
before or after discontinuation of study drug. Twenty ALT/
AST abnormalities occurred within 3 mo after discontinua-
tion of study drug; 14 were in the TDF group and six were in
the placebo group. With the exception of one, all were grade
1 or 2 events (i.e., less than 85 U/l). One participant (who
received TDF) had a grade 3 AST abnormality, which resolved
within 1 mo.
Adverse events. A total of 320 (75%) women in the TDF
group and 310 (72%) women in the placebo group had at
least one AE. The most frequently reported AEs (occurring in
5% of participants in either treatment group) are summar-
ized in Table 3. There were no significant differences between
treatment groups for any AEs within system organ classes.
Similar results were obtained among HBsAg-positive partic-
ipants.
Twenty–two SAEs were reported during the study (nine in
the TDF group and 13 in the placebo group) in 17
participants. The majority of the SAEs were hospitalizations
due to malaria (nine events). No SAEs were considered
related to study drug. Two deaths occurred in Cameroon
during the course of the study; both occurred approximately
5 mo after study drug dispensation was suspended. One was
due to an unspecified condition with anemia (the participant
had been randomized to placebo), and one was suspected to
be related to an induced abortion (the participant had been
randomized to TDF). Study drug was not discontinued in any
participant by the site investigator or study clinician because
of an AE or abnormal laboratory result.
Effectiveness: HIV Incidence
For the primary effectiveness analysis, women in Cameroon,
Ghana, and Nigeria contributed 232.6 person-years of follow-
up in the TDF group and 241.3 person-years in the placebo
group.
Eight seroconversions occurred among participants while
receiving the study drug. Two HIV infections were diagnosed
in participants randomized to TDF (rate ¼ 0.86 per 100
person-years) and six in participants receiving placebo (rate¼
2.48 per 100 person-years), yielding a rate ratio of 0.35 (95%
confidence interval¼ 0.03–1.93; p¼ 0.24). With the exception
of two participants (one randomized to TDF and one to
placebo), all seroconversions were detected on or after the
second monthly follow-up visit. Blood specimens were
available from one of the two participants who seroconverted
while on TDF; standard genotypic analysis revealed no
evidence of drug resistance mutations. An additional six
participants seroconverted after study drug was discontinued
in Cameroon (four had been randomized to TDF and two to
placebo).
DISCUSSION
Interpretation and Overall Evidence
Our data provide an encouraging rationale for additional
research to evaluate oral antiretroviral drugs as prophylaxis
against HIV infection. No significant differences in safety
.......................................................................................................................................................................................
Table 1. Demographic Characteristics
Demographic Measure/Subcategory TDF Group Placebo Group
Age (in years) Mean (SD) 23.6 (4.0) 23.5 (3.9)
Range 18–34 18–34
Total 427 432
Marital status, n (%) Not married, not living with man 396 (92.7) 385 (89.1)
Not married, living with man 23 (5.4) 31 (7.2)
Married, not living with man 6 (1.4) 16 (3.7)
Married, living with man 2 (0.5) 0 (0.0)
Total 427 432
Years of school completed, n (%) 12 400 (93.7) 408 (94.4)
.12 27 (6.3) 24 (5.6)
Mean (SD) 8.3 (3.5) 7.9 (3.5)
Range 0–19 0–17
Total 427 432
Ever been pregnant, n (%) No 110 (25.8) 120 (27.8)
Yes 317 (74.2) 312 (72.2)
Total 427 432
If have been pregnant, number of pregnancies Mean (SD) 2.4 (1.7) 2.4 (3.1)
Range 1–12 0–50
Total 317 312
Currently using a contraceptive, n (%) No 206 (48.2) 206 (47.7)
Oral 17 (4.0) 23 (5.3)
Injectable 6 (1.4) 7 (1.6)
IUD 2 (0.5) 0 (0.0)
Condom 193 (45.2) 192 (44.4)
Other 3 (0.7) 4 (0.9)
Total 427 432
Had any sexually transmitted infection in past 6 mo, n (%) No 257 (60.2) 248 (57.4)
Yes 170 (39.8) 184 (42.6)
Total 427 432
SD, standard deviation.
doi:10.1371/journal.pctr.0020027.t001..
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patterns occurred among participants receiving daily oral
TDF compared with those receiving placebo, consistent with
results seen in previous treatment studies [2].
No randomized clinical studies have been completed to
evaluate the effectiveness of antiretroviral drugs as pre- or
post-exposure prophylaxis against HIV infection. In a recent
Cochrane review [20], only one case-control study of health-
care workers after needlestick injury was identified. HIV-
infected workers had significantly lower odds of having taken
zidovudine prophylaxis after exposure than those who did
not seroconvert (odds ratio¼ 0.19, 95% confidence interval¼
0.06–0.52) [21]. The effectiveness of antiviral prophylaxis
after sexual exposure is not known [22]. Non-randomized
observations of post-exposure prophylaxis (PEP) are difficult
to interpret because there could be underlying and uncon-
trolled differences between those who seek and use PEP and
those who do not, including differences in behavior and
access to information and medications. Furthermore, PEP or
event-driven dosing is limited by the fact that failures can
occur when treatment is not initiated because the risk of the
exposure is not recognized [23]. We address this limitation of
event-driven dosing in this study by recommending daily
dosing for frequently exposed persons—a strategy referred to
as pre-exposure prophylaxis. Because public health practice
should be guided by evidence, especially in settings having
competing demands for scarce public health resources, an
urgent need exists for antiviral prophylaxis for HIV to be
evaluated in randomized, placebo-controlled trials, as we
report here. Further effectiveness studies in populations of
women at high risk for acquiring HIV should proceed
rapidly.
The premature stopping of the study in Cameroon and
Nigeria limited the amount of follow-up safety and effective-
ness data obtained in this study. Furthermore, AEs and
.......................................................................................................................................................................................
Table 2. Laboratory Abnormalities during Scheduled Follow-Up in Ghana and Cameroon
Abnormality Grade TDF Group (n ¼ 363) Placebo Group (n ¼ 368) Rate Ratio (95%
Confidence Interval)
TDF versus Placebo
Number
with Event
Rate (per 100
Person-Years)
Number
with Event
Rate (per 100
Person-Years)
ALT 1þ (.42 U/l) 33 17.8 27 13.5 1.3 (0.8–2.3)
2þ (.85 U/l) 8 4.0 6 2.8 1.4 (0.4–4.9)
3þ (.170 U/l) 0 0.0 2 0.9 0.0 (0.0–5.6)
4 (.340 U/l) 0 0.0 0 0.0 —
AST 1þ (.42 U/l) 27 14.1 19 9.3 1.5 (0.8–2.9)
2þ (.85 U/l) 4 2.0 6 2.8 0.7 (0.1–2.9)
3þ (.170 U/l) 0 0.0 3 1.4 0.0 (0.0–2.5)
4 (.340 U/l) 0 0.0 0 0.0 —
Creatinine 1þ (.0.5 mg/dl from baseline) 13 6.5 15 7.1 0.9 (0.4–2.0)
2þ (.2.0 mg/dl) 0 0.0 0 0.0 —
3þ (.3.0 mg/dl) 0 0.0 0 0.0 —
4þ (.6.0 mg/dl) 0 0.0 0 0.0 —
Phosphorus 1þ (,2.2 mg/dl) 16 8.3 21 10.4 0.8 (0.4–1.6)
2þ (,2.0 mg/dl) 1 0.5 2 0.9 0.5 (0.0–10.0)
3þ (,1.5 mg/dl) 1 0.5 0 0.0 —
4 (,1.0 mg/dl) 0 0.0 0 0.0 —
doi:10.1371/journal.pctr.0020027.t002..
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Table 3. Selected Treatment-Emergent AEs Reported in 5% in Any Treatment Group (All Sites Combined)
Category AE TDF Group (n ¼ 427) Placebo Group (n ¼ 432)
Number of
Events
Number of
Women
Percent of
Women
Number of
Events
Number of
Women
Percent of
Women
Gastrointestinal Abdominal
pain NOS
28 24 5.6 26 22 5.1
Flatulence 27 22 5.2 16 15 3.5
General Asthenia 23 23 5.4 28 27 6.3
Infections Malaria NOS 200 127 29.7 227 134 31.0
Metabolism Anorexia 35 31 7.3 31 26 6.0
Nervous system Headache 59 55 12.9 63 52 12.0
Dizziness 38 33 7.7 37 33 7.6
Renal and
urinary
Urinary tract
infection NOS
28 23 5.4 17 15 3.5
Reproductive
system
Vaginal candidiasis 157 96 22.5 145 95 22.0
Respiratory Nasopharyngitis 15 15 3.5 30 29 6.7
NOS, not otherwise specified.
doi:10.1371/journal.pctr.0020027.t003..
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laboratory abnormalities in the TDF group may have been
diluted by lower than expected product use due to missed
visits, drug stoppage due to pregnancy, and other reasons for
non-use of study drug. The overall rate of HIV infection while
women were on TDF or placebo in Ghana, Cameroon, and
Nigeria was too low to demonstrate a reduction in risk for
those assigned to the TDF group.
TDF is active against HBV, and is recommended for
treatment of HBV infection in Europe and by many experts
[24–27]. Transaminase increases have been observed in up to
25% of patients stopping anti-HBV drugs after receiving
therapy for clinically important HBV infection, characterized
by pre-treatment elevated ALT or AST or signs of liver
fibrosis [28]. No flares of ALT or AST were observed among
those with HBV infection in this study, although our analysis
was limited to 23 TDF-treated women with reactive tests for
HBsAg. The rate of HBV flares after withdrawing TDF may be
low among people with normal baseline liver tests and no
signs or symptoms of advanced liver disease, such as the
women enrolled here. Additional data on the use of TDF in
persons with circulating HBsAg are needed to confirm the
results observed in this study.
We expected the HIV incidence in the placebo group to be
no less than five per 100 person-years, over twice that we
observed in this study. Thus, our power was less than
anticipated. The lower than expected HIV incidence may be
due in part to at least four factors: (1) the incidence rate was
estimated from both our experience in earlier trials in a
similar population and from current prevalence data; it was
not specifically measured in each population before starting
the study; (2) intense and consistent HIV/sexually transmitted
infection prevention services and messages were provided to
the study participants during the trial; (3) the effect of taking
a pill every day for HIV prevention may have served as a
timely reminder of imminent HIV risk such that participants
modified their behavior to incorporate precautions against
infection such as increased use of condoms; and (4)
participants who elect to join clinical trials may be more
inclined to safer behavior than those in their community who
do not participate. Indeed, reductions of risk behavior have
been observed in open label studies of PEP [23,29].
Generalizability
As a new HIV prevention approach, prophylactic use of TDF
could be used with other prevention strategies such as
condoms to reduce the number of people who become
infected with HIV. Larger phase 3 studies to conclusively
determine the safety, effectiveness, and feasibility of using
TDF (either alone or in combination with other antiretro-
virals) as chemoprophylaxis against HIV infection in both
women and men are needed.
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